Payment overview · 2025
General Payments
$1,573.89
90 reported records · 31 companies
Healthcare provider profile · identity verified
Christopher Lamar Miller, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DOTHAN, AL · NPI 1477528990
Verified facts
What the public records show
CMS Open Payments records show Christopher Lamar Miller, M.D. received $1,573.89 in general payments during 2025 across 90 reported records.
AstraZeneca Pharmaceuticals LP accounted for 12.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 47 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Descovy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Isentress by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $200.44 | 12.7% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $158.72 | 10.1% | 12 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $150.34 | 9.6% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $135.74 | 8.6% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $112.29 | 7.1% | 11 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $96.12 | 6.1% | 2 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $78.01 | 5.0% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $64.75 | 4.1% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $50.58 | 3.2% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $50.23 | 3.2% | 2 | 2025 |
| Theratechnologies Inc. | Unresolved — no canonical attribution shown | $42.81 | 2.7% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $39.86 | 2.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $37.15 | 2.4% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$34.12 | 2.2% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $34.12 | 2.2% | 2 | 2025 |
| Urgo Medical North America, LLC | Unresolved — no canonical attribution shown | $31.89 | 2.0% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $23.65 | 1.5% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $22.32 | 1.4% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $21.86 | 1.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.28 | 1.2% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.90 | 1.2% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $18.25 | 1.2% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $17.79 | 1.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.30 | 1.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.74 | 1.1% | 1 | 2025 |
| Shionogi Inc | Unresolved — no canonical attribution shown | $16.10 | 1.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.92 | 0.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.63 | 0.9% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $14.52 | 0.9% | 1 | 2025 |
| Molnlycke Health Care US, LLC | Unresolved — no canonical attribution shown | $11.56 | 0.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $8.90 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,573.89 | 90 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $150.34 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $119.49 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $110.74 | 6 | 2025 |
Source payment records
|
|||||
| ACTIV.A.C. Normalized: activ a c |
Device | Solventum Corporation | $96.12 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $89.70 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $72.24 | 8 | 2025 |
Source payment records
|
|||||
| 3M Cavilon Normalized: 3m cavilon |
Device | Solventum Corporation | $70.31 | 1 | 2025 |
Source payment records
|
|||||
| PREVENA Normalized: prevena |
Device | Solventum Corporation | $70.31 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $70.10 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $52.72 | 5 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $50.58 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $50.23 | 2 | 2025 |
Source payment records
|
|||||
| EGRIFTA Normalized: egrifta |
Drug | Theratechnologies Inc. | $42.81 | 1 | 2025 |
Source payment records
|
|||||
| TROGARZO Normalized: trogarzo |
Drug | Theratechnologies Inc. | $42.81 | 1 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $40.88 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $39.86 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $39.23 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $37.15 | 2 | 2025 |
Source payment records
|
|||||
| APLIGRAF Normalized: apligraf |
Device | Organogenesis Inc. | $37.13 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.77 | 4 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $34.12 | 2 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $34.12 | 1 | 2025 |
Source payment records
|
|||||
| VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP Normalized: vashe wound solution 250 ml 8 5 fl oz flip top cap |
Device | Urgo Medical North America, LLC | $31.89 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $31.63 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $31.63 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $29.78 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $22.32 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| Fetroja Normalized: fetroja |
Drug | Shionogi Inc | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.92 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| Exufiber Normalized: exufiber |
Device | Molnlycke Health Care US, LLC | $11.56 | 1 | 2025 |
Source payment records
|
|||||
| Mepilex Ag Normalized: mepilex ag |
Device | Molnlycke Health Care US, LLC | $11.56 | 1 | 2025 |
Source payment records
|
|||||
| Mepilex Border Flex Normalized: mepilex border flex |
Device | Molnlycke Health Care US, LLC | $11.56 | 1 | 2025 |
Source payment records
|
|||||
| Mepilex Transfer Ag Normalized: mepilex transfer ag |
Device | Molnlycke Health Care US, LLC | $11.56 | 1 | 2025 |
Source payment records
|
|||||
| Tubigrip Normalized: tubigrip |
Device | Molnlycke Health Care US, LLC | $11.56 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $8.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 48 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 72 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
72 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
57 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 417 | 113 |
| Atorvastatin Calcium | Atorvastatin Calcium | 391 | 112 |
| Amlodipine Besylate | Amlodipine Besylate | 377 | 112 |
| Meloxicam | Meloxicam | 281 | 109 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 277 | 85 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 263 | 72 |
| Lisinopril | Lisinopril | 250 | 71 |
| Pioglitazone Hcl | Pioglitazone Hcl | 171 | 56 |
| Metformin Hcl Er | Metformin Hcl | 168 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 156 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 154 | 50 |
| Donepezil Hcl | Donepezil Hcl | 139 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 138 | 55 |
| Simvastatin | Simvastatin | 137 | 39 |
| Gabapentin | Gabapentin | 129 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 124 | 43 |
| Ezetimibe | Ezetimibe | 122 | 40 |
| Metformin Hcl | Metformin Hcl | 121 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 120 | 25 |
| Omeprazole | Omeprazole | 116 | 38 |
| Tramadol Hcl | Tramadol Hcl | 113 | 37 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 101 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 30 |
| Telmisartan | Telmisartan | 91 | 26 |
| Montelukast Sodium | Montelukast Sodium | 90 | 29 |
| Fenofibrate | Fenofibrate Nanocrystallized | 83 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 27 |
| Celecoxib | Celecoxib | 79 | 23 |
| Memantine Hcl | Memantine Hcl | 76 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 21 |
| Potassium Chloride | Potassium Chloride | 74 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 23 |
| Ozempic | Semaglutide | 72 | 16 |
| Sertraline Hcl | Sertraline Hcl | 70 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 24 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 64 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 63 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 61 | 17 |
| Trazodone Hcl | Trazodone Hcl | 61 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | suppressed |
| Eliquis | Apixaban | 57 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 56 | 20 |
| Allopurinol | Allopurinol | 55 | 16 |
| Efavirenz-Emtric-Tenofov Disop | Efavirenz/Emtricit/Tenofovr Df | 55 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 52 | 14 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 52 | 52 |
| Glimepiride | Glimepiride | 52 | 20 |
| Carvedilol | Carvedilol | 50 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 14 |
| Jardiance | Empagliflozin | 48 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 29 |
| Doxazosin Mesylate | Doxazosin Mesylate | 47 | 14 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 47 | 43 |
| Famotidine | Famotidine | 45 | 16 |
| Furosemide | Furosemide | 44 | 18 |
| Losartan Potassium | Losartan Potassium | 44 | 14 |
| Methocarbamol | Methocarbamol | 43 | 12 |
| Valacyclovir | Valacyclovir Hcl | 43 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 12 |
| Lorazepam | Lorazepam | 42 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Repatha Sureclick | Evolocumab | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 29 |
| Bumetanide | Bumetanide | 29 | 13 |
| Colchicine | Colchicine | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 17 |
| Stribild | Elviteg/Cob/Emtri/Tenofo Disop | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 18 |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 14 |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 12 |
| Irbesartan | Irbesartan | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Prednisone | Prednisone | 16 | 11 |
| Spironolactone | Spironolactone | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 15 |
| Isentress | Raltegravir Potassium | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | 11 |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 15 | suppressed |
| Oxazepam | Oxazepam | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Ethosuximide | Ethosuximide | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Armodafinil | Armodafinil | 11 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Lyrica | Pregabalin | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,573.89 · 90 records | AstraZeneca Pharmaceuticals LP | 3M Cavilon, ACTIV.A.C., AIRSUPRA, APLIGRAF, AUSTEDO XR, COLLAGENASE SANTYL, EGRIFTA, EVENITY, Exufiber, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FREESTYLE LIBRE 3, Fetroja, Flucelvax, INGREZZA, INJECTAFER, INSPIRE, JARDIANCE, Korlym, Leqembi, MOUNJARO, Mepilex Ag, Mepilex Border Flex, Mepilex Transfer Ag, NEXLETOL, NURTEC ODT, Ozempic, PREVENA, PURAPLY WOUND MATRIX, QUTENZA, REPATHA, REXULTI, Rybelsus, SYMPLICITY G3, Sunosi, TROGARZO, The Cologuard Plus Collection Kit, Tubigrip, UBRELVY, VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP, VERQUVO, VYNDAQEL, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error